A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC

This study is testing a combination of two drugs — HLX43 (an anti-HER3 antibody) and serplulimab (an immunotherapy drug targeting PD-1) — as a pre-surgery (neoadjuvant) treatment for people with stage II–IIIB non-small cell lung cancer (NSCLC) that does not carry specific genetic mutations that would be better treated with targeted drugs. **You may be eligible if...** - You are between 18 and 75 years old - You have confirmed NSCLC at stage II to IIIB - Your tumor does not have actionable mutations (like EGFR or ALK changes) - You have not yet received any cancer treatment for this lung cancer - You and your surgeon agree that surgery aiming for complete removal of the cancer is possible - You have at least one measurable tumor on imaging - Your heart and major organ functions are within acceptable ranges **You may NOT be eligible if...** - Your cancer contains small cell lung cancer components - You have previously received chemotherapy, radiation, or immunotherapy for any lung cancer - You have significant heart disease, including recent heart attack or uncontrolled heart failure - You have active autoimmune disease, active infections, or HIV - You have active hepatitis B or C (controlled hepatitis B with very low viral load may be acceptable) - You have had a previous organ transplant - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.